BiotechTube

CDI-31244 + SOF/VEL

Phase 2Completed
0 watching 0 views this week⚡ Active
44
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Chronic Hepatitis C

Conditions

Chronic Hepatitis C

Trial Timeline

Jun 26, 2018 → Jun 7, 2019

NCT ID
NCT03501550

About CDI-31244 + SOF/VEL

CDI-31244 + SOF/VEL is a phase 2 stage product being developed by Cocrystal Pharma for Chronic Hepatitis C. The current trial status is completed. This product is registered under clinical trial identifier NCT03501550. Target conditions include Chronic Hepatitis C.

Hype Score Breakdown

Clinical
17
Activity
12
Company
2
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT03501550Phase 2Completed

Competing Products

20 competing products in Chronic Hepatitis C

See all competitors
ProductCompanyStageHype Score
macitentan 10 mgBML, Inc.Phase 3
76
KPL-716 + PlaceboKiniksa PharmaceuticalsPhase 2
47
TERN-701Terns PharmaceuticalsPhase 1/2
38
Fludarabine + Cyclophosphamide + PRGN-3007PrecigenPhase 1
28
LY3556050 + PlaceboEli LillyPhase 2
52
THB001Third Harmonic BioPhase 1
25
BriquilimabJasper TherapeuticsPhase 1/2
33
BriquilimabJasper TherapeuticsPhase 1/2
33
BriquilimabJasper TherapeuticsPhase 2
44
Empagliflozin + Matching placeboEli LillyPhase 3
77
LY3461767 + PlaceboEli LillyPhase 1
33
Pirtobrutinib + Venetoclax + RituximabEli LillyPhase 3
77
LY3526318 + PlaceboEli LillyPhase 2
52
PirtobrutinibEli LillyPhase 2
52
Ibrutinib + LY3214996Eli LillyPhase 1
33
Pirtobrutinib + AcalabrutinibEli LillyPhase 2
52
LYR-210Lyra TherapeuticsPhase 2
44
LYR-220 Design 1 (Part 1 only) + LYR-220 Design 2 (Part 1 and Part 2) + Bilateral sham procedure control (Part 2)Lyra TherapeuticsPhase 2
44
480 Mometasone Furoate Sinus Drug DepotLyra TherapeuticsPhase 1
25
LYR-210 + Sham procedure controlLyra TherapeuticsPhase 3
69

Other Products from Cocrystal Pharma

CDI-988 + PlaceboPhase 1/2
33
CDI-31244 + PlaceboPhase 1
25
CC-42344 + PlaceboPhase 1
25
CDI-988 + PlaceboPhase 1
25